Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean farina sadeghi (2 results)?
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial.
Mohazzab A, Fallah Mehrabadi MH, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan SA, Sadeghi F, Rezaei Mokarram A, Haji Moradi M, Razaz SH, Taghdiri M, Ansarifar A, Lotfi M, Khorasani A, Nofeli M, Masoumi S, Boluki Z, Erfanpoor S, Bagheri Amiri F, Esmailzadehha N, Filsoof S, Mohseni V, Ghahremanzadeh N, Safari S, Shahsavan M, Bayazidi S, Raghami Derakhshani M, Rabiee MH, Golmoradi-Zadeh R, Khodadoost B, Solaymani-Dodaran M, Banihashemi SR. Mohazzab A, et al. Among authors: sadeghi f. J Pharm Sci. 2023 Dec;112(12):3012-3021. doi: 10.1016/j.xphs.2023.09.027. Epub 2023 Oct 11. J Pharm Sci. 2023. PMID: 37832918 Clinical Trial.
Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial.
Dodaran MS, Banihashemi SR, Es-Haghi A, Mehrabadi MHF, Nofeli M, Mokarram AR, Mokhberalsafa L, Sadeghi F, Ranjbar A, Ansarifar A, Mohazzab A, Setarehdan SA, Bagheri Amiri F, Mohseni V, Hajimoradi M, Ghahremanzadeh N, Razzaz SH, Masoomi S, Taghdiri M, Bagheri M, Lofti M, Khorasani A, Ghader M, Safari S, Shahsavn M, Kalantari S. Dodaran MS, et al. Among authors: sadeghi f. Vaccines (Basel). 2023 Feb 16;11(2):455. doi: 10.3390/vaccines11020455. Vaccines (Basel). 2023. PMID: 36851334 Free PMC article.
Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial.
Solaymani-Dodaran M, Kalantari S, Banihashemi SR, Es-Haghi A, Nofeli M, Mohazzab A, Mokhberalsafa L, Sadeghi F, Mokaram AR, Moradi MH, Razaz SH, Taghdiri M, Lotfi M, Setarehdan SA, Masoumi S, Ansarifar A, Ebrahimi S, Esmailzadehha N, Boluki Z, Khoramdad M, Molaipour L, Rabiei MH, Amiri FB, Filsoof S, Bani-Vaheb B, Derakhshani MR, Bayazidi S, Golmoradizadeh R, Shahsavan M, Safari S, Ghahremanzadeh N, Mohseni V, Erfanpoor S, Fallah Mehrabadi MH. Solaymani-Dodaran M, et al. Among authors: sadeghi f. Heliyon. 2024 Mar 3;10(5):e27370. doi: 10.1016/j.heliyon.2024.e27370. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463808 Free PMC article.
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S, Banihashemi SR, Mokhbaeralsafa L, Kalantari S, Es-Haghi A, Nofeli M, Rezaei Mokarram A, Sadeghi F, Hajimoradi M, Razaz SH, Taghdiri M, Lotfi M, Khorasani A, Ansarifar A, Masoumi S, Mohazzab A, Filsoof S, Mohseni V, Shahsavan M, Gharavi N, Setarehdan SA, Rabiee MH, Fallah Mehrabadi MH, Solaymani-Dodaran M. Erfanpoor S, et al. Among authors: sadeghi f. BMC Med. 2024 Feb 20;22(1):78. doi: 10.1186/s12916-024-03295-1. BMC Med. 2024. PMID: 38378570 Free PMC article. Clinical Trial.